Status:
COMPLETED
Plexin B2 Gene Expression and Polymorphisms in Psoriasis
Lead Sponsor:
South Valley University
Conditions:
Psoriasis Vulgaris
Eligibility:
All Genders
24-64 years
Phase:
PHASE1
Brief Summary
Patients will be randomly assigned (1:1:1 ) either to ; NB-UVB photo-therapy alone , Acitretin therapy alone or NB-UVB photo-therapy combined with Acitretin therapy randomization will be done by close...
Detailed Description
Study Setting: Qena University Hospital, Department of Dermatology ,Venereology\& Andrology. Study subjects: the study will include psoriasis Vulgaris patients who Come to the out patients dermatolog...
Eligibility Criteria
Inclusion
- Patients of both sexes. Diagnosed clinically with moderate to severe Psoriasis Vulgaris.
- patients able to swallow tablet and receive Narrow band Ultraviolet B phototherapy without any contraindication
Exclusion
- Pregnancy , lactation \& women intent to become pregnant within 3 year after discontinuation of acitretin Patients with Hyperlipidemia Patients with mental problems and depression Patients with a history of malignancies, renal \& liver diseases. Patients with a history of any inflammatory diseases as atopic dermatitis , asthma ulcerative colitis ) and Crohn's disease Patients received NB-UVB phototherapy in the last 6 months. Patients treated with methotrexate or biologic agents and any systemic treatment of psoriasis.
Key Trial Info
Start Date :
September 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05184348
Start Date
September 1 2021
End Date
March 30 2023
Last Update
September 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine , South Valley University
Qina, Egypt